Abivax (ABVX) Interest Expenses (2024 - 2026)

Abivax (ABVX) has reported Interest Expenses for 3 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 21.05% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at $128.9 million (up 978.63% YoY), while the FY2025 annual figure was $130.1 million, up 616.4% from the prior year.
• Interest Expenses came in at -$5.6 million for Q1 2026 at Abivax, down from $249.4 million in the prior quarter.
• The five-year high for Interest Expenses was $249.4 million in Q4 2025, with the low at -$108.8 million in Q3 2025.
• Average Interest Expenses over 3 years is $15.1 million, with a median of -$6.1 million recorded in 2025.
• The largest YoY upside for Interest Expenses was 594.14% in 2025 against a maximum downside of 1068.9% in 2025.
• Year by year, Interest Expenses stood at $35.9 million in 2024, then jumped by 594.14% to $249.4 million in 2025, then sank by 102.24% to -$5.6 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered -$5.6 million, $249.4 million, and -$108.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.